Central Nervous System Neoplasms
"Central Nervous System Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Descriptor ID |
D016543
|
| MeSH Number(s) |
C04.588.614.250 C10.551.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Neoplasms".
This graph shows the total number of publications written about "Central Nervous System Neoplasms" by people in this website by year, and whether "Central Nervous System Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 0 | 2 |
| 2007 | 3 | 1 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 7 | 0 | 7 |
| 2011 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 6 | 0 | 6 |
| 2015 | 4 | 0 | 4 |
| 2016 | 5 | 2 | 7 |
| 2017 | 10 | 0 | 10 |
| 2018 | 5 | 1 | 6 |
| 2019 | 10 | 1 | 11 |
| 2020 | 5 | 0 | 5 |
| 2021 | 10 | 0 | 10 |
| 2022 | 5 | 0 | 5 |
| 2023 | 8 | 0 | 8 |
| 2024 | 6 | 1 | 7 |
| 2025 | 8 | 0 | 8 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Neoplasms" by people in Profiles.
-
Burden of Central Nervous System Cancer in the United States, 1990-2021. JAMA Neurol. 2026 Jan 01; 83(1):35-48.
-
Exploration of possible association of BRIP1 pathogenic variants with central nervous system cancers in an institutional cohort. J Med Genet. 2025 Oct 20; 62(11):720-723.
-
Translational advancement of immunotherapeutics against pediatric central nervous system tumors. Adv Cancer Res. 2025; 167:327-358.
-
The promise of immunotherapy for central nervous system tumours. Nat Rev Immunol. 2026 Mar; 26(3):213-229.
-
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089.
-
Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis. Clin Cancer Res. 2025 Apr 14; 31(8):1400-1406.
-
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 02; 220:115308.
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Cancer Med. 2024 Nov; 13(21):e70376.